甲状腺疾患治療の世界市場規模：薬剤タイプ別、疾患別、投与経路別、地域範囲別および予測

甲状腺疾患治療市場の規模と予測

甲状腺障害治療市場規模は、2024年に22億米ドルと評価され、2026～2032年にかけてCAGR 3.17%で成長し、2032年には28億米ドルに達すると予測されています。

• 甲状腺疾患治療とは、レボチロキシンや抗甲状腺剤などの薬剤を用いて甲状腺機能低下症や甲状腺機能亢進症などの状態をコントロールすることです。これらの治療は、甲状腺ホルモンレベルを回復させ、症状を軽減することを目的としています。
• 現在、甲状腺機能亢進症と甲状腺機能低下症の治療には、それぞれ放射性ヨードと甲状腺ホルモン補充療法が使われています。重症の場合は手術も考慮されます。定期的なモニタリングにより、効率的な管理が可能になります。
• 将来的には、オーダーメイド医療、標的治療、遺伝子編集の進歩が治療の中心になる可能性があります。新たな医薬品は、副作用を最小限に抑えながら治療結果を改善し、より正確な管理を提供する可能性があります。

世界の甲状腺障害治療市場力学

世界の甲状腺疾患治療市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

• 発生率の増加：発生率の増加：甲状腺機能低下症や甲状腺機能亢進症などの甲状腺疾患の発生が増加しており、発見率や認知度の向上も手伝って、より良い治療法へのニーズが高まっている
• 治療の進歩：製剤の改善やオーダーメイド治療などの医薬品イノベーションにより、治療の有効性と魅力が向上し、市場の成長が促進されます。
• 人口の高齢化：甲状腺の問題を抱えやすい高齢者の増加が、加齢に関連した甲状腺疾患に適した代替治療への需要を高めています。
• ヘルスケアへのアクセス：新興国におけるヘルスケアインフラとアクセスの向上により、診断と治療の利用可能性が高まり、これまで顧みられなかった領域での市場成長が促進されます。

主要課題

• 認識不足：甲状腺疾患に関する知識や教育が不十分なため、診断や治療が遅れ、市場の潜在力が低下する可能性があります。
• アクセスの制限：農村部や恵まれない地域での不十分なヘルスケアインフラが診断や治療の妨げとなり、市場の成長を制限する可能性があります。
• 副作用と問題：甲状腺疾患による治療の副作用や問題は、患者のコンプライアンス違反につながり、市場全体の受容性を低下させる可能性があります。

主要動向

• 高度診断：先進的診断機器や画像診断技術の向上により、甲状腺疾患の早期かつ正確な発見が可能になりました。
• 生物製剤と標的療法：甲状腺疾患の根本的な原因に対処するための生物製剤と標的治療の開発と導入により、新たな治療法の選択肢がもたらされます。
• 遠隔医療とデジタルヘルス：遠隔医療とデジタルヘルス技術は、遠隔モニタリングや遠隔管理にますます使用されるようになり、患者の治療へのアクセスや治療のアドヒアランスを向上させています。

目次

第1章 世界の甲状腺疾患治療市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の甲状腺疾患治療市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の甲状腺疾患治療市場：薬剤タイプ別

• 概要
• レボチロキシン
• リオチロニン
• プロピルチオウラシル
• イミダゾール系化合物
• β遮断薬

第6章 世界の甲状腺疾患治療市場：疾患別

• 概要
• 甲状腺機能低下症
• 甲状腺機能亢進症

第7章 甲状腺疾患治療の世界市場：エンドユーザー別

• 概要
• 経口
• 静脈注射

第8章 甲状腺疾患治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の甲状腺疾患治療市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• AbbVie, Inc.
• Mylan N.V.
• Merck & Co., Inc.
• Pfizer, Inc.
• Abbott Laboratories
• Allergan plc
• Bayer AG
• Novartis AG
• Sanofi S.A.
• GlaxoSmithKline plc.

第11章 主要開発

• 製品上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Thyroid Disorder Treatment Market Size And Forecast

Thyroid Disorder Treatment Market size was valued at USD 2.2 Billion in 2024 and is projected to reach USD 2.8 Billion by 2032 growing at a CAGR of 3.17% from 2026 to 2032.

• Thyroid disorder treatment is controlling conditions such as hypothyroidism and hyperthyroidism using medications such as levothyroxine or antithyroid agents. These treatments are intended to restore thyroid hormone levels and reduce symptoms.
• Radioactive iodine and thyroid hormone replacement therapy are currently used to treat hyperthyroidism and hypothyroidism, respectively. Surgery may be considered in severe situations. Regular monitoring enables efficient management.
• In the future, treatments may center on customized medicine, targeted therapeutics and advances in gene editing. Emerging medicines may provide more precise management, improving outcomes while minimizing side effects.

Global Thyroid Disorder Treatment Market Dynamics

The key market dynamics that are shaping the global Thyroid Disorder Treatment Market include:

Key Market Drivers:

• Increasing Incidence: Rising occurrences of thyroid problems, including as hypothyroidism and hyperthyroidism, are driving need for better therapies, aided by increasing detection rates and awareness.
• Advancements in Treatment: Pharmaceutical innovations, such as improved medication formulations and tailored therapies, improve treatment efficacy and appeal, promoting market growth.
• Aging Population: The expanding older population, which is more prone to thyroid problems, adds to the demand for therapeutic alternatives suited to age-related thyroid conditions.
• Healthcare Access: Increasing healthcare infrastructure and access in emerging countries increases diagnostic and treatment availability, boosting market growth in previously neglected areas.

Key Challenges:

• Lack of Awareness: Inadequate knowledge and education about thyroid problems might result in delayed diagnosis and treatment, diminishing market potential.
• Limited Access: Inadequate healthcare infrastructure in rural or disadvantaged areas might impede diagnosis and treatment, limiting market growth.
• Adverse Effects and Problems: Treatment side effects and problems from thyroid disorders might lead to patient noncompliance and reduce overall market acceptance.

Key Trends:

• Advanced Diagnostics: Improvements in advanced diagnostic instruments and imaging techniques have resulted in earlier and more accurate detection of thyroid problems.
• Biologics and Targeted Therapies: The development and implementation of biologic medications and targeted therapies to address the underlying causes of thyroid problems, hence providing new therapeutic choices.
• Telemedicine and Digital Health: Telemedicine and digital health technologies are increasingly being used for remote monitoring and management, hence enhancing patient access to care and treatment adherence.

Global Thyroid Disorder Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global Thyroid Disorder Treatment Market:

North America:

• According to Verified Market Research, North America is expected to dominate the global Thyroid Disorder Treatment Market.
• North America is likely to lead the worldwide thyroid disease treatment market due to its sophisticated healthcare infrastructure, high prevalence of thyroid disorders and major expenditure in R&D.
• The region's strong medical facilities and high levels of awareness help to maintain its leadership position, which is reinforced by ongoing advancements in treatment and diagnostics.

Asia Pacific:

• According to Verified Market Research, Asia Pacific is fastest growing region in global Thyroid Disorder Treatment Market.
• Asia-Pacific is the fastest-growing area in the worldwide thyroid disease treatment market, due to growing healthcare investments, rising thyroid condition prevalence and greater access to modern medical technologies. The region's high economic growth and improved healthcare facilities help to boost market expansion.

Global Thyroid Disorder Treatment Market: Segmentation Analysis

The Global Thyroid Disorder Treatment Market is segmented on the basis of Drug Type, Disease, Route of Administration, and Geography.

Thyroid Disorder Treatment Market, By Drug Type

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based Compounds
• Beta-blockers

Based on Drug Type, The market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compounds, Beta-blockers. Levothyroxine is the most common drug type in the global thyroid disease treatment market, used to treat hypothyroidism and maintain normal thyroid hormone levels.

Thyroid Disorder Treatment Market, By Disease

• Hypothyroidism
• Hyperthyroidism

Based on Disease, The market is segmented into Hypothyroidism and Hyperthyroidism. Hypothyroidism dominates the worldwide thyroid problem treatment market due to its higher prevalence than hyperthyroidism. The requirement for lifelong hormone replacement therapy creates increasing market demand and treatment possibilities.

Thyroid Disorder Treatment Market, By End-User

• Oral
• Intravenous

Based on End-User, The market is segmented into Oral and Intravenous. The oral category leads the global thyroid disease therapy market due to its convenience, ease of administration and patient preference. Oral medicines are commonly used to treat thyroid problems.

Key Players

The "Global Thyroid Disorder Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie, Inc., Mylan N.V., Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Allergan plc, Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

• Global Thyroid Disorder Treatment Market Recent Developments
• In December 2023, Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited, reached an agreement with Sandoz AG to acquire its Chinese business. This strategic move was consistent with Aspen's strategy goal of increasing its footprint in China by using Sandoz's proven portfolio, infrastructure and experienced team for future growth in the region.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THYROID DISORDER TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL THYROID DISORDER TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DRUG TYPE

• 5.1 Overview
• 5.2 Levothyroxine
• 5.3 Liothyronine
• 5.4 Propylthiouracil
• 5.5 Imidazole-based Compounds
• 5.6 Beta-blockers

6 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DISEASE

• 6.1 Overview
• 6.2 Hypothyroidism
• 6.3 Hyperthyroidism

7 GLOBAL THYROID DISORDER TREATMENT MARKET, BY END-USER

• 7.1 Overview
• 7.2 Oral
• 7.3 Intravenous

8 GLOBAL THYROID DISORDER TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL THYROID DISORDER TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 AbbVie, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Mylan N.V.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merck & Co., Inc.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Pfizer, Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Abbott Laboratories
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Allergan plc
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bayer AG
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Novartis AG
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Sanofi S.A.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 GlaxoSmithKline plc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research